Arcus Biosciences, Inc. (NYSE:RCUS) Director Yasunori Kaneko Purchases 20,000 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) Director Yasunori Kaneko bought 20,000 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was bought at an average price of $10.06 per share, with a total value of $201,200.00. Following the acquisition, the director now owns 28,400 shares in the company, valued at approximately $285,704. This trade represents a 238.10 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Arcus Biosciences Trading Down 2.7 %

Shares of NYSE RCUS opened at $9.87 on Friday. Arcus Biosciences, Inc. has a twelve month low of $9.85 and a twelve month high of $20.10. The firm has a market cap of $1.04 billion, a PE ratio of -3.13 and a beta of 0.84. The business has a fifty day simple moving average of $13.46 and a two-hundred day simple moving average of $15.42. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $36.00 million during the quarter, compared to the consensus estimate of $29.38 million. Analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RCUS has been the topic of several recent analyst reports. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a research note on Thursday, November 7th. HC Wainwright upgraded shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the company from $18.00 to $24.00 in a report on Wednesday. Morgan Stanley decreased their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Finally, Bank of America cut their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $30.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RCUS. Jane Street Group LLC boosted its position in Arcus Biosciences by 59.8% during the third quarter. Jane Street Group LLC now owns 217,041 shares of the company’s stock valued at $3,319,000 after purchasing an additional 81,193 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Arcus Biosciences by 11.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock valued at $8,669,000 after buying an additional 59,536 shares in the last quarter. GSA Capital Partners LLP grew its position in shares of Arcus Biosciences by 17.8% in the 3rd quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock worth $2,866,000 after buying an additional 28,307 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of Arcus Biosciences by 146.9% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company’s stock worth $15,684,000 after acquiring an additional 610,219 shares in the last quarter. Finally, Barclays PLC lifted its position in Arcus Biosciences by 49.0% during the third quarter. Barclays PLC now owns 118,693 shares of the company’s stock valued at $1,816,000 after acquiring an additional 39,015 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.